When you think of small molecule drugs, you think of the binding site, or a “lock-and-key" analogy– similarly, no biologic is complete without fully characterizing and understanding its epitope, or binding site - it’s a must have. Before you settle for a suboptimal approach, give our epitope mapping platform a try. Our technique, epitope mapping by hydroxyl radical protein footprinting (HRPF), circumvents all of the major drawbacks of current approaches — it’s ultra-fast, universally compatible, works in native conditions, and all of our projects are guaranteed.
Common epitope mapping techniques, like x-ray crystallography and cryoEM, are prone to failure, prohibitively expensive, and incompatible with certain classes of targets (e.g. integral membrane proteins and megacomplexes). Other approaches developed to circumvent these issues, like mutagenesis, peptide scanning, and hydrogen-deuterium exchange mass spectrometry, expose the target to non-native conditions, miss non-linear and non-obvious epitopes, and can be unreliable and unreproducible. So what’s a developer to do?
Mapping the binding sites (or epitopes) of antibodies and their target antigens is critical for understanding their mechanism of action as well as filing patent claims. In addition, understanding the motion and dynamics of the antigen in response to binding provides additional insight to advance therapeutic candidates and maximize efficacy.
Epitope mapping is often relegated to the later stages of discovery because of the challenges with capturing the structural detail of the antibody/antigen interaction. There is one clear cause: the techniques that are commonly used for epitope mapping, including x-ray crystallography, peptide scanning, mutagenesis, and hydrogen-deuterium exchange (HDX), all have significant limitations and drawbacks.
Our orthogonal technique for protein footprinting is called hydroxyl radical protein footprinting - we use our proprietary platform to label proteins and detect changes in solvent accessibility of protein side chains. Top pharmaceutical companies and biotechnology firms are working with Immuto and deploying epitope mapping by HRPF to condense the discovery process and curtail the millions of dollars spent on discovery.
This paper provides ample information and evidence to understand our approach, provides hard data and case studies so you can evaluate its utility, details where it can be applied, and describes how it will give your organization an advantage in streamlining drug discovery and development.
Submit the form below and we'll send the white paper right to your inbox.
Get a practical, applied look at epitope mapping in biologic drug development.
See why epitope mapping is important for antibody discovery.
Explore the current techniques: Hydrogen Deuterium eXchange and Hydroxyl Radical Protein Footprinting
See the benefits of using PLIMB for HRF.